文献速递抗菌药物管理药物不良反应与药物警戒

新型生物标志物辅助抗菌药物管理项目活动的评估

Evaluation of the Use of Novel Biomarkers to Augment Antimicrobial Stewardship Program Activities.
PubMed 文献 · Pharmacotherapy · 2018-01-16

本文通过系统文献检索评估新型生物标志物作为抗菌药物管理工具的价值。降钙素原可辅助鉴别细菌与病毒感染、指导停药决策及预测死亡;β-d-葡聚糖、白色念珠菌芽管抗体和半乳甘露聚糖有助于疑似真菌感染并减少不恰当抗真菌药使用;肾上腺髓质素和可溶性髓系细胞触发受体-1可能有助于死亡预测和确定经验性抗菌药需求。这些标志物各有局限,应与临床征象或其他标志物联合使用,管理项目应针对最可能获益人群并制定机构指南促进正确解读。

要点

  • 降钙素原可辅助鉴别细菌与病毒感染、指导抗菌药停药决策并预测死亡。
  • β-d-葡聚糖、白色念珠菌芽管抗体和半乳甘露聚糖有助于疑似真菌感染管理。
  • 生物标志物应与临床征象或其他标志物联合使用,避免 indiscriminate 应用于所有患者。

核心结论

  • 新型生物标志物有望辅助抗菌药物管理活动,但存在局限,应与临床征象、症状或其他生物标志物联合使用。
  • 管理项目应针对最可能获益的人群使用生物标志物,并通过机构指南教育临床医生确保正确使用和解读。

研究设计与样本

  • 采用 PubMed/MEDLINE 数据库进行系统文献检索,评估新型生物标志物作为抗菌药物管理工具的补充价值。

主要发现

  • 降钙素原可能帮助临床医生鉴别细菌与病毒感染、辅助抗菌药停药决策并预测死亡。
  • β-d-葡聚糖、白色念珠菌芽管抗体和半乳甘露聚糖在疑似真菌感染中有用,可能减少不恰当抗真菌药使用。
  • 肾上腺髓质素和可溶性髓系细胞触发受体-1可能有助于死亡预测和确定经验性抗菌药需求。

临床怎么用

  • 抗菌药物管理项目应考虑最可能获益的人群使用生物标志物,避免 indiscriminate 应用于所有患者。
  • 管理项目应通过机构指南促进临床医生教育,确保生物标志物的适当使用和解读。

局限性

  • 所评估的生物标志物并非没有局限性,应与临床征象、症状或其他生物标志物联合使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As antimicrobial stewardship increasingly receives worldwide attention for improving patient care by optimizing antimicrobial therapy, programs are evaluating new tools that may augment antimicrobial stewardship activities. Biomarkers are objective, accurate, and reproducible measures that provide information about medical conditions. A systematic literature search using PubMed/MEDLINE databases was performed to evaluate the use of novel biomarkers as additions to the antimicrobial stewardship armamentarium. Procalcitonin may help clinicians discriminate between bacterial and viral infections, help with antimicrobial discontinuation decisions, and predict mortality. β-d-glucan, Candida albicans germ tube antibody, and galactomannan are useful in suspected fungal infections and may reduce inappropriate antifungal use. Adrenomedullin and soluble triggering receptor on myeloid cells-1 may be useful for mortality prediction and the determination of a need for empiric antibacterials. Although studies evaluating these biomarkers are promising, these biomarkers are not without limitations and should be used in combination with clinical signs, symptoms, or other biomarkers. For successful implementation of biomarker use, stewardship programs should consider the populations most likely to benefit, without using them indiscriminately in all patients. Antimicrobial stewardship programs should facilitate education of clinicians through institutional guidelines to ensure the appropriate use and interpretation of these biomarkers.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Stover KR, Kenney RM, King ST, et al. Evaluation of the Use of Novel Biomarkers to Augment Antimicrobial Stewardship Program Activities. Pharmacotherapy. 2018. PMID: 29245184. doi:10.1002/phar.2069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。